HerAnova named Femtech Company of the Year at Health Tech World Awards

HerAnova Lifesciences won Femtech Company of the Year at the Health Tech World Awards 2026 for its work in endometriosis and women’s health. The win spotlights HerResolve™, the company’s non-invasive blood test designed to help speed diagnosis for symptomatic women.

Why it matters: - Endometriosis affects about 1 in 10 women of reproductive age. - Diagnosis often takes seven to 10 years. - HerAnova says HerResolve™ is designed to give clinicians a non-invasive triage tool, which could help patients move to treatment decisions faster and reduce reliance on surgery for diagnosis. - The award also signals growing attention on femtech tools that address long-standing gaps in women’s health care.

What happened: - HerAnova Lifesciences was named Femtech Company of the Year at the Health Tech World Awards 2026. - Health Tech World announced the winners at a ceremony on Oct. 28, 2026. - The award was sponsored by Cross-Border Impact Ventures. - Farideh Bischoff, PhD, chief medical officer and head of diagnostics at HerAnova Lifesciences, accepted the award on behalf of the company.

The details: - HerAnova’s flagship diagnostic, HerResolve™, is a blood-based rule-in test for endometriosis in symptomatic women. - In a clinical validation study published in the Journal of Minimally Invasive Gynecology, HerResolve™ showed an AUC of 94%, 80% sensitivity and 97.5% specificity. - HerResolve™ is a multi-omic assay that combines microRNA, protein and a hormone biomarker using a proprietary machine learning framework. - HerAnova describes HerResolve™ as the first and only commercially available non-invasive blood test developed to detect endometriosis. - The test is currently available at select IVF and reproductive medicine centers across the U.S. - HerAnova says the test is meant to complement existing clinical pathways and help identify patients who may benefit from further diagnostic evaluation or empirical treatment. - The company’s stated goal is to reserve surgery for treatment rather than diagnosis. - Penny Wan, co-founder and chairwoman of HerAnova, framed the message for patients as: “It’s not you, it’s endometriosis.” - The company’s announcement is available online.

Between the lines: - The award gives HerAnova third-party validation at a time when women’s health diagnostics are drawing more investor and clinical attention. - HerResolve™ sits in a category where speed, accuracy and non-invasiveness matter because many patients face years of symptoms before getting answers. - The company is positioning its test not as a replacement for all care, but as a step that could shorten the path to specialist evaluation.

What’s next: - HerAnova is likely to use the award to build visibility with clinicians, patients and potential partners. - Broader adoption will depend on how the test performs in practice, how quickly access expands beyond select centers and how clinicians integrate it into existing endometriosis workups. - The company says it continues to advance diagnostics, therapeutics, medical devices and data analytics in women’s health.

The bottom line: - HerAnova won a major femtech award by tying a clinical need — faster, less invasive endometriosis diagnosis — to a commercially available test already in use at select U.S. centers.